Skip to main content
TipRanks
Go Ultimate75% OFF

Apimeds Pharmaceuticals US, Inc. (APUS) Stock Price & Analysis

31 Followers

APUS Stock Chart & Stats

$1.60-$0.14(-8.05%)
At close: 4:00 PM EST
$2$4$6Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$1.51 - $1.77
52-Week Range
$1.51 - $59.70
Previous Close
$1.74
Volume
N/A
Average Volume (3M)
123.82K
Market Cap
$2.96M
Enterprise Value
$24.00M
Total Cash (Recent Filing)
$17.91K
Total Debt (Recent Filing)
$9.61M
Price to Earnings (P/E)
―
Beta
2.44
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Modest debt relative to equity gives APUS a stronger financial cushion than its earnings profile would suggest. This reduces near-term interest and refinancing pressure and preserves some flexibility to fund commercialization while the company works toward a more sustainable operating model.

High Gross Margin

The very high reported gross margin indicates that the emerging revenue base has attractive economics before operating costs. If APUS can scale demand and control its substantial overhead, this structure could support meaningful incremental contribution and improve the path toward eventual profitability.

Blockchain Infrastructure Expansion

The BlockAssure agreement broadens APUS’s operating exposure into insurance and reinsurance infrastructure, including development, hosting, security audits and maintenance. That creates a multi-year service relationship and could establish a durable technology role if milestones and continued operations are delivered successfully.

Bears Say

Severe Unprofitability

APUS’s current revenue base is far too small to absorb its operating cost structure, leaving the company deeply unprofitable despite strong gross margin. Persistent losses weaken retained capital and make future improvement dependent on rapid commercialization, disciplined spending, or additional financing.

Persistent Cash Burn

Negative operating and free cash flow show that APUS is not yet funding operations internally. Continued burn can consume its balance-sheet cushion and require further financing before revenues scale, creating ongoing capital-allocation pressure and potentially limiting investment in its growth initiatives.

Funding And Dilution Risk

The history of negative equity and changing equity levels suggests that the present balance-sheet cushion has not eliminated funding dependence. If losses continue, APUS may need external capital, and the pack specifically identifies further dilution as a risk to existing shareholders.

Apimeds Pharmaceuticals US, Inc. News

APUS FAQ

What was Apimeds Pharmaceuticals US, Inc.’s price range in the past 12 months?
Apimeds Pharmaceuticals US, Inc. lowest stock price was $1.51 and its highest was $59.70 in the past 12 months.
What is Apimeds Pharmaceuticals US, Inc.’s market cap?
Apimeds Pharmaceuticals US, Inc.’s market cap is $2.96M.
When is Apimeds Pharmaceuticals US, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Apimeds Pharmaceuticals US, Inc.’s earnings last quarter?
Apimeds Pharmaceuticals US, Inc. released its earnings results on Nov 18, 2026. The company reported $5.766 earnings per share for the quarter.
Is Apimeds Pharmaceuticals US, Inc. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Apimeds Pharmaceuticals US, Inc. pay dividends?
Apimeds Pharmaceuticals US, Inc. does not currently pay dividends.
What is Apimeds Pharmaceuticals US, Inc.’s EPS estimate?
Apimeds Pharmaceuticals US, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Apimeds Pharmaceuticals US, Inc. have?
Apimeds Pharmaceuticals US, Inc. has 1,847,626 shares outstanding.
What happened to Apimeds Pharmaceuticals US, Inc.’s price movement after its last earnings report?
Apimeds Pharmaceuticals US, Inc. reported an EPS of $5.766 in its last earnings report. Following the earnings report the stock price went down -3.077%.
Which hedge fund is a major shareholder of Apimeds Pharmaceuticals US, Inc.?
Currently, no hedge funds are holding shares in APUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology